Latest news with #HG-CT-1
Associated Press
3 days ago
- Business
- Associated Press
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Secures £451,250 to continue its Phase 1 Clinical Trials And Director's Dealing LONDON, UK / ACCESS Newswire / June 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ('Hemogenyx Pharmaceuticals' or the 'Company') is pleased to announce that it has raised gross proceeds of £451,250 (before expenses) via an allotment to Vladislav Sandler of 250,000 new ordinary shares of £0.01 each ('New Ordinary Shares') at an issue price of 180.5p (the 'Issue Price'). The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ('R/R AML'). As shareholders will be aware, the first two patients have now been infused with HG-CT-1. Issuance of the New Ordinary Shares The Company is currently unable to issue and admit the New Issue Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus. Consequentially, this fundraise involves the acceptance by Vladislav Sandler, CEO and director of the Company to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article1(4)(i) and 1(5) (h) of the UK Prospectus Regulation. Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the 'Purchaser'). Warrants Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence ('Exercise Price'), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price. Total Voting Rights Application will be made for the 250,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 13 June ('Admission'). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,593,539. The above figure of 4,593,539 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company will keep the market informed of future developments as trials proceed. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 'We are pleased to have secured funding from a committed investor at a premium to the prevailing market price - an indication of their confidence in the long-term potential of Hemogenyx and our HG-CT-1 program. This support enables us to continue advancing our Phase I clinical trial without undue dilution and at a pivotal moment in the development of our therapy for relapsed/refractory AML.' Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Director's Dealing Notification Enquiries: About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Hemogenyx Pharmaceuticals PLC press release
Yahoo
14-05-2025
- Business
- Yahoo
Hemogenyx Pharmaceuticals PLC Announces Pediatric Amendment to Clinical Protocol
Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML LONDON, UNITED KINGDOM / / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has filed an amendment to the clinical protocol for its ongoing Phase I clinical trial of HG-CT-1 to include pediatric patients with relapsed/refractory acute myeloid leukemia ("R/R AML"). HG-CT-1 is the Company's CAR-T therapy, currently undergoing clinical trials in adults for the treatment of R/R AML. This amendment, filed with the U.S. Food and Drug Administration (FDA), seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting. The expansion reflects the Company's commitment to broadening the potential impact of HG-CT-1 and addressing a critical unmet medical need in pediatric oncology. The amendment builds on the Company's progress to date in the adult cohort of the trial, in which the first two patients have already been treated. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are pleased to take this important step toward making HG-CT-1 available to pediatric patients who currently have very few therapeutic options. The inclusion of children and adolescents in the trial not only reflects our commitment to addressing urgent medical needs across age groups but also supports the broader potential of HG-CT-1 as a transformative therapy for AML." Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@ Peter Redmond, Director SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy
LONDON, GB / / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ("R/R AML") in adults. This milestone follows the successful first-in-human treatment with HG-CT-1, which demonstrated a favorable initial safety profile with no adverse effects observed, and the subsequent recruitment of the second patient. Together, these milestones mark steady progress in the clinical development of HG-CT-1 and reinforce the Company's commitment to advancing treatment options for patients with limited therapeutic alternatives. The Phase I trial is a dose-escalation study designed to assess the safety profile of HG-CT-1 and to collect data on key secondary endpoints, including anti-leukemic activity, overall survival, progression-free survival, and duration of response. The Company believes that continued clinical execution will not only advance a potentially transformative treatment for adult patients with limited therapeutic options but also generate long-term value for shareholders by establishing HG-CT-1 as a platform-defining asset in the field of hematologic malignancies. While the current trial is focused on adult patients, successful initial outcomes would pave the way for a pediatric trial - an area of significant unmet medical need in AML, where few effective treatment options exist for children. Further updates on the clinical trial will be provided in due course. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "The treatment of a second patient with HG-CT-1 marks another critical step in the development of our CAR-T therapy for relapsed or refractory AML. The ability to move forward with dosing reflects the capabilities of our scientific and manufacturing teams and further validates our platform. We remain deeply focused on executing the clinical program with rigor and care, and on our mission to bring potentially life-saving treatments to patients in need." Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@ Peter Redmond, Director SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
17-03-2025
- Business
- Associated Press
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options. The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly. Further updates on the clinical trial will be provided in due course. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 'The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need.' Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Enquiries: About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit
Yahoo
17-03-2025
- Business
- Yahoo
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options. The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly. Further updates on the clinical trial will be provided in due course. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need." Market Abuse Regulation (MAR) DisclosureCertain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@ Peter Redmond, Director SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on ACCESS Newswire Sign in to access your portfolio
